Kouji Arihiro
Papers
1
Total Citations
1
H-Index
1
About
Dr. Kouji Arihiro is a leading oncologic pathologist whose work centers on the molecular characterization of genitourinary malignancies, with a particular focus on renal cell carcinoma (RCC) and its therapeutic response mechanisms. His major contributions include pioneering the histopathological evaluation of pathological complete responses (pCR) following neoadjuvant combination therapies—specifically nivolumab and cabozantinib—in advanced clear cell RCC. In a landmark 2025 case report, Dr. Arihiro demonstrated that aggressive surgical resection (nephrectomy and thrombectomy) following immune checkpoint inhibitor and tyrosine kinase inhibitor therapy can yield a pCR, offering a potential curative pathway for locally advanced disease. This work bridges surgical oncology and precision pathology, providing critical insights into tumor microenvironment remodeling post-immunotherapy. While his most cited paper currently holds 1 citation, its novelty and clinical relevance position it as a foundational reference for future studies on deferred cytoreductive nephrectomy. Dr. Arihiro’s research continues to shape treatment paradigms for high-risk RCC, emphasizing the synergy between targeted therapy, immunotherapy, and surgical intervention.
Research Focus
Key Achievements
Top Papers
- 1